16/06/2024 Francesco Rocca, investimenti in Italia, Johnson & Johnson, Johnson & Johnson Innovative Medicine, Jorge Lopez, Mario Sturion, Nicola Calandrini, Oladapo Ajayi, studio The European House - Ambrosetti